Baduanjin training improves motor symptoms and anxiety more than brisk walking in Parkinson's disease
This randomized controlled trial enrolled 32 patients with early- to mid-stage Parkinson's disease (Hoehn and Yahr stages 1–2.5) over 12 weeks. Participants were assigned to either Baduanjin training (40-minute sessions five times weekly) or brisk walking (40-minute sessions five times weekly), with outcomes assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) and other measures.
Main results showed that the Baduanjin group demonstrated significantly greater improvements in MDS-UPDRS-III scores than the brisk walking group (P < 0.05), with specific benefits on the axial subscale at 6 weeks (P = 0.038) but not at 12 weeks (P = 0.060). Baduanjin also reduced anxiety more than brisk walking (P = 0.014), improved cognition (P = 0.015), and showed superior gait parameters in Timed Up and Go duration, turning time, and trunk sagittal angular velocity (all P < 0.05). Depression improved within the Baduanjin group only (P = 0.015), while both groups improved in sleep and quality of life.
Safety and tolerability were not reported. Key limitations include the small sample size of 32 patients, and funding or conflicts of interest were not reported. Practice relevance suggests Baduanjin may offer a non-pharmacological rehabilitation option, but clinicians should consider the limited evidence and lack of safety data.